How is the Lyell Immunopharma Inc today?

The Lyell Immunopharma Inc today is trading in the down by -2.38% at 0.41.

What is Lyell Immunopharma Inc Annual Revenue?

Lyell Immunopharma Inc Annual Revenue fell 53.08%, in the last year to $0.06 M. Its sector's average revenue growth for the last fiscal year was 8.75%.

What is Lyell Immunopharma Inc Annual Net Profit?

Lyell Immunopharma Inc Annual Net Profit fell 46.18% in the last year to $342.99 M. Its sector's average net profit growth for the last fiscal year was -11.16%.

What is Lyell Immunopharma Inc Price to Earning Ratio?

Lyell Immunopharma Inc Price to Earning Ratio is -0.36, which is negative.

What is Lyell Immunopharma Inc Stock Price?

Lyell Immunopharma Inc Stock Price fell 84.64% and underperformed its sector by 96.73% in the past year.

What is Lyell Immunopharma Inc Quarterly Revenue?

Lyell Immunopharma Inc Quarterly Revenue rose 133.33% YoY to $0.01 M. Its sector's average revenue growth YoY for the quarter was 3.13%.

What is Lyell Immunopharma Inc Quarterly Net profit?

Lyell Immunopharma Inc Quarterly Net profit rose 13.96% YoY to $52.2 M. Its sector's average net profit growth YoY for the quarter was -200.49%.

What is Lyell Immunopharma Inc Debt to Equity Ratio?

Lyell Immunopharma Inc Debt to Equity Ratio of 0.15 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

What is Lyell Immunopharma Inc Return on Equity(ROE)?

Lyell Immunopharma Inc Return on Equity(ROE) for the last financial year was -66.1%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is Lyell Immunopharma Inc Mutual Fund Holding?

Lyell Immunopharma Inc Mutual Fund Holding decreased by 0.45% in the last quarter to 14.75.

What is Lyell Immunopharma Inc Institutional Holding?

Lyell Immunopharma Inc Institutional Holding decreased by 0.68% in the last quarter to 52.73.

Lyell Immunopharma Inc XNAS: LYEL

Lyell Immunopharma Inc Live Share Price Today, Share Analysis and Chart

Name: Lyell Immunopharma Inc: Is Infosys Ltd. worth buying?
Item: Lyell Immunopharma Inc
Rating: 1.07458325
Author: Trendlyne DVM scores

about

Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline include...

0.41 -0.01 (-2.38%)

New 52W Low in past week

486.8K XNAS Volume

XNAS 21 May, 2025 4:00 PM (EDT)

Not Eligible

-

Expensive Valuation

15.3 / 100

Technically Bearish

27.7 / 100

1

1Yr Price target upside is 95%

2 analysts

Lyell Immunopharma Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Lyell Immunopharma Inc FAQ

How is Lyell Immunopharma Inc today?

Lyell Immunopharma Inc today is trading in the red, and is down by -2.38% at 0.41.

How has Lyell Immunopharma Inc performed historically?

Lyell Immunopharma Inc is currently trading down -2.38% on an intraday basis. In the past week the stock rose 2.50%. stock has been down -37.88% in the past quarter and fell -84.64% in the past year. You can view this in the overview section.